• Area of Focus: Healthcare
  • Geography: EMEA
  • Stage: Buyout
  • Investment Year: 2026
  • Website Link

Sebia

Sebia is a leading provider of in vitro diagnostic instruments and kits used in the diagnosis of multiple myeloma, diabetes, genetic blood disorders, and autoimmune disorders. Founded in 1967 and headquartered in Lisses, France, the company operates across c. 150 countries.